MicroPort NeuroScientific Corporation
HHKEX:21728.06
HKD
-0.26
(-3.19%)
ISIN
KYG6083E1098
CUSIP
G6083E109
Return %
Stock
S&P 500
1Y
-38.32
14.20
3Y
-33.43
81.12
5Y
- -
68.34
Capital Structure
CNY
•
in mil. unless spec.Working Capital
CNY
•
in mil. unless spec.Growth Rates
CNY
•
in mil. unless spec.Semi-annual Revenue
CNY
•
in mil. unless spec.Semi-annual Earnings Per Share
CNY
•
in mil. unless spec.Semi-annual Dividends Per Share
CNY
•
in mil. unless spec.Company Description
- CEO
- Zhi Yong Xie
- Full Time Employees
- 547
- Sector
- Health technology
- Industry
- Medical specialties
- Address
- Yangming Tower Shanghai SH China 201318
- IPO Date
- Jul 15, 2022
- Website
- microportneurosci.com
- Similar Companies
- Business
- MicroPort NeuroTech Limited is a leading Chinese neuro-interventional medical device company specializing in the research, development, manufacture, and sale of innovative medical devices for the treatment of cerebrovascular diseases. Its core product portfolio covers three major clinical areas: hemorrhagic stroke, cerebral atherosclerotic stenosis, and acute ischemic stroke (AIS). The company’s main products include Tubridge® Stent, NUMEN® Coil, Bridge® Vertebral Artery Stent, Neurohawk® Stent Thrombectomy Device, NeuroGuard® Neurovascular Balloon Guide Catheter, Safecer™ Embolic Protection Device, and PathFinder™ Carotid Artery Balloon Dilatation Catheter. It also provides integrated clinical solutions such as the AND procedure and NEXT procedure, which combine different devices to address complex neurovascular conditions. MicroPort NeuroTech operates primarily in China and has expanded its market presence to over 2,400 hospitals domestically, while also engaging in international markets including the United States, Europe, South Korea, and Brazil. Founded in 2012 and headquartered in Shanghai, MicroPort NeuroTech is a subsidiary of MicroPort Scientific Corporation. The company went public on the Hong Kong Stock Exchange in July 2022 under the ticker 2172.HK. Recent strategic advancements include a significant equity investment in Israeli medical device company Rapid Medical, which focuses on neuroendovascular therapy. MicroPort NeuroTech became the largest shareholder in Rapid Medical following this deal, strengthening its product portfolio and expanding its global sales network. The partnership enables joint marketing and registration of Rapid Medical’s flagship products in Greater China and other international markets. In 2023, MicroPort NeuroTech issued a positive profit alert projecting a net profit increase of at least 36% compared to the previous year, reflecting strong growth driven by successful innovative product launches and expanded market penetration. The company continues to invest heavily in research and development to maintain its leadership in the neurovascular medical field, focusing on innovation and industrialization aimed at providing comprehensive stroke treatment solutions and improving patient outcomes globally. Its operations leverage independent intellectual property rights and core manufacturing technologies, supporting over 120 cerebrovascular stenting procedures daily. MicroPort NeuroTech’s recent product milestones include the first implantation of Tubridge™ Plus in China, further consolidating its innovative product line and clinical adoption. The company’s comprehensive strategy positions it as a total solution provider for cerebrovascular interventions, with an increasing footprint in international markets alongside solid domestic leadership.